Cost-effectiveness of adjuvant systemic therapies for patients with high-risk melanoma in Europe: a model-based economic evaluation

por Mulder, E.E.A.P., Smit, L., Grünhagen, D.J., Verhoef, C., Sleijfer, S., van der Veldt, A.A.M., Uyl-de Groot, C.A.
Publicado 2021

Validation of a clinicopathological and gene expression profile model for sentinel lymph node metastasis in primary cutaneous melanoma

por Mulder, E.E.A.P., Dwarkasing, J.T., Tempel, D., van der Spek, A., Bosman, L., Verver, D., Mooyaart, A.L., van der Veldt, A.A.M., Verhoef, C., Nijsten, T.E.C., Grunhagen, D.J., Hollestein, L.M.
Publicado 2020

The meaning of screening: detection of brain metastasis in the adjuvant setting for stage III melanoma

por Derks, S.H.A.E., de Joode, K., Mulder, E.E.A.P., Ho, L.S., Joosse, A., de Jonge, M.J.A., Verhoef, C., Grünhagen, D.J., Smits, M., van den Bent, M.J., van der Veldt, A.A.M.
Publicado 2022

Early discontinuation of PD-1 blockade upon achieving a complete or partial response in patients with advanced melanoma: the multicentre prospective Safe Stop trial

por Mulder, E. E. A. P., de Joode, K., Litière, S., ten Tije, A. J., Suijkerbuijk, K. P. M., Boers-Sonderen, M. J., Hospers, G. A. P., de Groot, J. W. B., van den Eertwegh, A. J. M., Aarts, M. J. B., Piersma, D., van Rijn, R. S., Kapiteijn, E., Vreugdenhil, G., van den Berkmortel, F. W. P. J., Hoop, E. Oomen-de, Franken, M. G., Ryll, B., Rutkowski, P., Sleijfer, S., Haanen, J. B. A. G., van der Veldt, A. A. M.
Publicado 2021